Also known as: Alendronate sodium
Alendronic acid is a bisphosphonate that inhibits osteoclastic bone resorption with no direct effect on bone formation. The bone formed during treatment with alendronic acid is of normal quality.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Alendronic acid is the active ingredient of these drugs:
Spain
South Africa
Hong Kong
Brazil
Hong Kong
Poland
New Zealand
Hong Kong
Poland
Italy
Ecuador
Italy
Estonia
Hong Kong South Africa
Ecuador
Italy
Hong Kong
Cyprus Estonia Finland Germany Ireland
Brazil
Brazil
France Ireland Netherlands
Brazil
South Africa
Tunisia
Australia South Africa
Italy
Ecuador
Brazil
Ecuador
South Africa
Australia
South Africa
Tunisia
Austria Brazil Canada France Germany
South Africa
Ireland
Italy
South Africa
Italy
Brazil
Cyprus
Singapore
Estonia
Ecuador
Italy
Brazil
Hong Kong
South Africa
Italy
Italy
Austria
South Africa
Ecuador
Brazil
Lithuania Poland
South Africa
Brazil
Poland
South Africa
Brazil
Brazil
Hong Kong
Ireland
Ecuador
Austria
South Africa
Ecuador
Poland
South Africa
Brazil
Ecuador
Italy
Italy
Hong Kong
South Africa
Ireland
Estonia Poland
Spain
Spain
Estonia France
Estonia Germany Hong Kong Ireland
Alendronic acid is also found within below combination drugs:
ADROVANCE , ALENCALCI D3 , ALENDIL D , BENTEXO , BONENDRO , FONATPLUS , FOSALEN D3 , FOSAMAX D , FOSAMAX PLUS , FOSASTAD , FOSAVANCE , OSTEOMIX PLUS , OSTEONATE PLUS , OSTEOPLUS D , TEBONEVA , TRIDEPOS , VANTAVO
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):